Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

February 28, 2003

Conditions

Heparin-Induced ThrombocytopeniaThrombosis

Interventions

DRUG

bivalirudin

Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.

Trial Locations (1)

Duke Clinical Research Institute, Duke University Medical Center, Durham